Share Prices & Company Research

Market News

21 Oct 2019 | 13:59

Futura Medical completes dosing for erectile dysfunction treatment trial

Futura Medical said that all patients had now completed dosing in a European study of a treatment for erectile dysfunction.

Futura Medical said it remained on track to deliver headline data from the Phase 3 study by the end of 2019.

In addition, patient recruitment had recently been completed for the required 12 month open-label extension study.

'We are extremely pleased to have achieved this important milestone and look forward to the Phase 3 data read out, which is on track to deliver headline efficacy and safety data in December this year, a key value inflection point for the company,' chief executive James Barder said.

'It is estimated that one in six men will experience some form of erectile dysfunction in their lives.'

'We believe MED2005 will offer new hope to erectile dysfunction suffers, in an area that has seen little innovation for nearly two decades and has the potential to be a first line treatment option for erectile dysfunction.'

At 1:59pm: (LON:FUM) Futura Medical PLC share price was +2p at 33p

Story provided by StockMarketWire.com
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.